No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

doi:10.1016/j.medmal.2020.03.006

Clinical Trial

. 2020 Jun;50(4):384.

doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

J M Molina¹, C Delaugerre², J Le Goff², B Mela-Lima³, D Ponscarme³, L Goldwirt⁴, N de Castro³

Affiliations

¹ Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.
² Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.
³ Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.
⁴ Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.

PMID: 32240719
PMCID: PMC7195369
DOI: 10.1016/j.medmal.2020.03.006

Clinical Trial

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

J M Molina et al. Med Mal Infect. 2020 Jun.

. 2020 Jun;50(4):384.

doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.

Authors

J M Molina¹, C Delaugerre², J Le Goff², B Mela-Lima³, D Ponscarme³, L Goldwirt⁴, N de Castro³

Affiliations

¹ Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.
² Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.
³ Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.
⁴ Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.

PMID: 32240719
PMCID: PMC7195369
DOI: 10.1016/j.medmal.2020.03.006

No abstract available

PubMed Disclaimer

Cited by

Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena.
Samaddar A, Grover M, Nag VL. Samaddar A, et al. Front Pharmacol. 2020 Sep 17;11:585888. doi: 10.3389/fphar.2020.585888. eCollection 2020. Front Pharmacol. 2020. PMID: 33041830 Free PMC article. Review.
[QTc interval prolongation in patients infected with SARS-CoV-2 and treated with antiviral drugs].
Esmel-Vilomara R, Dolader P, Sabaté-Rotes A, Soriano-Arandes A, Gran F, Rosés-Noguer F. Esmel-Vilomara R, et al. An Pediatr (Barc). 2022 Mar;96(3):213-220. doi: 10.1016/j.anpedi.2021.04.009. Epub 2021 Apr 20. An Pediatr (Barc). 2022. PMID: 33995537 Free PMC article. Spanish.
COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports.
Prasad A, Panhwar S, Hendel RC, Sheikh O, Mushtaq Z, Dollar F, Vinas A, Alraies C, Almonani A, Nguyen TH, Amione-Guerra J, Foster MT, Sisson C, Anderson A, George JC, Kutkut I, Guareña Casillas JA, Badin A. Prasad A, et al. Am Heart J. 2020 Aug;226:174-187. doi: 10.1016/j.ahj.2020.06.009. Epub 2020 Jun 15. Am Heart J. 2020. PMID: 32599258 Free PMC article. Review.
A framework to deal with uncertainty in the age of COVID-19.
Ng QX, De Deyn MLZQ, Loke W, Chan HW. Ng QX, et al. Asian J Psychiatr. 2020 Dec;54:102263. doi: 10.1016/j.ajp.2020.102263. Epub 2020 Jun 20. Asian J Psychiatr. 2020. PMID: 32603984 Free PMC article. No abstract available.
Use of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis.
Millet C, Narvaneni S, Shafeek F, Roman S, Mechineni A, Manickam R. Millet C, et al. Cureus. 2022 Feb 9;14(2):e22061. doi: 10.7759/cureus.22061. eCollection 2022 Feb. Cureus. 2022. PMID: 35340525 Free PMC article.

See all "Cited by" articles

References

1. Wang M., Cao R., Zhang L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed
1. Al-Bari A.A. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5:e00293. - PMC - PubMed
1. Gautret P., Lagier J.C., Parola P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomised clinical trial. Int J Antimicrob Agents. 2020 [ahead of print] - PMC - PubMed
1. Chen J., Liu D., Lui L., et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 COVID-19) J Zhejiang Univ Sci. 2020;03:03-.
1. Roques P., Thiberville S.D., Dupuis-Maguiraga L., et al. Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection. Viruses. 2018;10:268. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Wang M., Cao R., Zhang L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed

[2] Wang M., Cao R., Zhang L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed

[3] Al-Bari A.A. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5:e00293. - PMC - PubMed

[4] Al-Bari A.A. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5:e00293. - PMC - PubMed

[5] Gautret P., Lagier J.C., Parola P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomised clinical trial. Int J Antimicrob Agents. 2020 [ahead of print] - PMC - PubMed

[6] Gautret P., Lagier J.C., Parola P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomised clinical trial. Int J Antimicrob Agents. 2020 [ahead of print] - PMC - PubMed

[7] Chen J., Liu D., Lui L., et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 COVID-19) J Zhejiang Univ Sci. 2020;03:03-.

[8] Chen J., Liu D., Lui L., et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 COVID-19) J Zhejiang Univ Sci. 2020;03:03-.

[9] Roques P., Thiberville S.D., Dupuis-Maguiraga L., et al. Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection. Viruses. 2018;10:268. - PMC - PubMed

[10] Roques P., Thiberville S.D., Dupuis-Maguiraga L., et al. Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection. Viruses. 2018;10:268. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Affiliations

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources